U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C30H24N4O8
Molecular Weight 568.5336
Optical Activity UNSPECIFIED
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZILSARTAN MEDOXOMIL

SMILES

CCOC1=NC2=CC=CC(C(=O)OCC3=C(C)OC(=O)O3)=C2N1CC4=CC=C(C=C4)C5=CC=CC=C5C6=NOC(=O)N6

InChI

InChIKey=QJFSABGVXDWMIW-UHFFFAOYSA-N
InChI=1S/C30H24N4O8/c1-3-38-28-31-23-10-6-9-22(27(35)39-16-24-17(2)40-30(37)41-24)25(23)34(28)15-18-11-13-19(14-12-18)20-7-4-5-8-21(20)26-32-29(36)42-33-26/h4-14H,3,15-16H2,1-2H3,(H,32,33,36)

HIDE SMILES / InChI

Description

Azilsartan medoxomil (trade name Edarb) is an angiotensin II receptor blocker (ARB) that lowers blood pressure by blocking the action of angiotensin II, a vasopressor hormone. It is indicated for the treatment of hypertension to lower blood pressure which reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Azilsartan medoxomil may be used either alone or in combination with other antihypertensive agents such as chlorthalidone (CLD). As an ARB, azilsartan medoxomil selectively inhibits angiotensin II from binding to the angiotensin II type-1 receptor (AT1). This receptor inhibition provides the antihypertensive activity of azilsartan medoxomil because it blocks the pressor effects of angiotensin II. Azilsartan medoxomil is a prodrug of azilsartan. It is hydrolyzed to the active moiety, azilsartan, in the gastrointestinal (GI) tract during the absorption phase. Azilsartan medoxomil, in combination with the thiazide-like diuretic chlorthalidone, was more effective in lowering systolic BP than azilsartan plus HCTZ.

CNS Activity

Approval Year

Target InfoCondition Info

Condition Info

PMID

PMID

TitleDatePMID
TAK-536, a new AT1 receptor blocker, improves glucose intolerance and adipocyte differentiation.
2007 May
Azilsartan Medoxomil (Edarbi): The Eighth Angiotensin II Receptor Blocker.
2011 Oct
Differential pharmacology and benefit/risk of azilsartan compared to other sartans.
2012
A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists.
2013 Apr
Azilsartan, aliskiren, and combination antihypertensives utilizing renin-angiotensin-aldosterone system antagonists.
2014 Sep-Oct
Patent

Sample Use Guides

In Vivo Use Guide
The recommended dose in adults is 80 mg taken orally once daily. Consider a starting dose of 40 mg for patients who are treated with high doses of diuretics.
Route of Administration: Oral
Name Type Language
AZILSARTAN MEDOXOMIL
DASH   INN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
INN   USAN  
Official Name English
(5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL 2-ETHOXY-1-((2'-(5-OXO-2,5-DIHYDRO-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-YL)METHYL)-1H-BENZIMIDAZOLE-7-CARBOXYLATE
Systematic Name English
AZILSARTAN MEDOXOMIL [VANDF]
Common Name English
AZILSARTAN MEDOXOMIL [MI]
Common Name English
AZILSARTAN MEDOXOMIL [WHO-DD]
Common Name English
AZILSARTAN MEDOXOMIL [USAN]
Common Name English
EDARBI
Brand Name English
IPREZIV
Brand Name English
TAK 491
Code English
AZILSARTAN MEDOXOMIL [MART.]
Common Name English
TAK-491
Code English
AZILSARTAN MEDOXOMIL [ORANGE BOOK]
Common Name English
AZILSARTAN MEDOXOMIL [INN]
Common Name English
1H-BENZIMIDAZOLE-7-CARBOXYLIC ACID, 1-((2'-(2,5-DIHYDRO-5-OXO-1,2,4-OXADIAZOL-3-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-2-ETHOXY-, (5-METHYL-2-OXO-1,3-DIOXOL-4-YL)METHYL ESTER
Common Name English
Classification Tree Code System Code
WHO-ATC C09CA09
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
EMA ASSESSMENT REPORTS EDARBI (AUTHORIZED: HYPERTENSION)
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
WHO-ATC C09DA09
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
EMA ASSESSMENT REPORTS IPREZIV (WITHDRAWN: HYPERTENSION)
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
WHO-VATC QC09CA09
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
Code System Code Type Description
NCI_THESAURUS
C75110
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY
MERCK INDEX
M2173
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY Merck Index
RXCUI
1091642
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY RxNorm
EVMPD
SUB31560
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY
ChEMBL
CHEMBL2028661
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY
INN
8874
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY
PUBCHEM
11238823
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY
CAS
863031-21-4
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY
IUPHAR
6900
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY
EPA CompTox
863031-21-4
Created by admin on Tue Mar 06 11:15:35 UTC 2018 , Edited by admin on Tue Mar 06 11:15:35 UTC 2018
PRIMARY